Clinical Trial Update: Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating the BTK inhibitor ibrutinib in adults with newly diagnosed or relapsed/refractory primary CNS lymphoma and relapsed/refrac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | Phase 1, Phase 2 | Status: COMPLETED